FDA Software as a Medical Device (SaMD): Complete FDA Compliance Guide

Software solutions are the key component of the quickly evolving healthcare industry. From smartphone apps that track your heart rate to advanced AI algorithms that help radiologists identify cancer, digital health solutions are becoming more complex. 

A great invention is accompanied by great regulation and responsibility. Whether you’re a health tech startup founder or a physician with a great app idea, understanding what constitutes SaMD and how the FDA regulates it is crucial for turning your idea into a legally marketed product.

In this blog, you’ll know what FDA SaMD is, its essential aspects, and how it relates to broader medical device laws. This simplifies the process and enables you to innovate securely, confidently, and in complete compliance.

What Is FDA Software as a Medical Device (SaMD)?

The FDA defines Software as a Medical Device as software that is intended to be used for one or more medical purposes, but does not form part of a hardware medical device. If your app diagnoses, treats, prevents, or monitors a medical condition, it may be SaMD.

• Standalone Software Functionality – Unlike software installed in a medical device, like firmware in an insulin pump, SaMD works on general-purpose computer platforms such as smartphones, tablets, and cloud servers.
• Medical Purpose – The term “medical purpose” can refer to anything from processing MRI pictures to giving clinical decision assistance or even monitoring vital signs using wearable sensors.

Key Characteristics of FDA Software as a Medical Device

Understanding the distinguishing qualities of SaMD allows you to plan, build, and validate your solution more efficiently. 

Clinical Functionality

SaMD must carry out a clinical task, like identifying disease indicators in imaging data or recommending a dosage. This suggests that you’ll need to support your claims with clinical data and thorough documentation of the intended use.

Risk-Based Classification

The FDA defines SaMD according to the danger it poses to patients.

• Low Risk (Class I) – Minimal potential harm, such as general wellness apps.
• Moderate Risk (Class II) – Assists decision-making or monitors vital indicators.
• High risk (Class III) – Directly influences crucial treatment decisions, like software that controls radiation dosing.

Recognizing your risk class early on influences your regulatory strategy and documentation plan.

Regulatory Compliance and Quality Management

The FDA’s Quality System Regulation, which covers design controls, risk management, and corrective actions, must be followed by SaMD developers. Last-minute compliance problems can be avoided by putting in place a strong quality management system from the beginning. 

Interoperability and Cybersecurity

EHR systems and other devices often exchange patient data with SaMD; as a result, you need to create secure connection protocols, encrypt data, and set up threat monitoring. Maintaining interoperability reduces security threats while simultaneously enhancing the user experience.

Each of these characteristics necessitates meticulous planning, collaboration between clinical and engineering teams, and continuous dedication to both safety and innovation.

FDA SaMD Risk Classification Framework

The F.D.A have not developed a specific classification for Software as a Medical Device. If a software function is found to fall within the legal definition of medical devices, the FDA classifies it as Class I, II or III depending on its intended use, potential risk and the regulatory controls necessary to ensure reasonable assurance of safety and effectiveness.

FDA Medical Device Classes

• Class I: Lowest-risk devices generally subject to general controls. Some Class I devices are exempt from 510(k), but the exemption must be confirmed for the applicable regulation and product code.
• Class II: Moderate-risk devices subject to general and special controls. Most require a 510(k), while a novel device without a suitable predicate may follow the De Novo pathway.
• Class III: Highest-risk devices that may support or sustain life, prevent serious health impairment, or present a potentially unreasonable risk. These devices generally require Premarket Approval.

The IMDRF also provides a four-category SaMD risk framework. Categories I through IV are determined by the seriousness of the healthcare condition and whether the software informs, drives, treats, or diagnoses a clinical decision. 

Category I represents the lowest impact, while Category IV represents the highest. However, these IMDRF categories do not directly replace the FDA’s Class I, II, and III classifications.

Key factors affecting FDA Software as a Medical Device classification include:

• Intended use and indications for use
• Target patient population
• Seriousness of the disease or condition
• Clinical significance of the software output
• Potential harm if the software fails
• Availability of a legally marketed predicate
• Controls needed to manage identified risks

FDA Regulatory Pathways for Software as a Medical Device

1. Pre-Submission Engagement

Attend a Pre-Submission meeting with the FDA before starting development. This first conversation aids in defining regulatory requirements, determining which clinical trials are required, and optimizing your validation approach.

2. 510(k) Clearance: De Novo vs. PMA

Depending on your risk class and predicate devices like existing, comparable devices on the market. 

• 510(k) Clearance – Show “substantial equivalence” with a predicate device typical for Class II.
• De Novo Classification – For innovative, low-to-moderate risk devices that lack a predicate.
• Premarket Approval – A rigorous clinical examination of high-risk (Class III) technologies.

3. Labeling and Directions for Use

Instructions and labels need to be simple to read and comprehend. The exact process, any contraindications, and the intended use must all be specified. When writing these sections, doctors, technical writers, and UX designers frequently need to work together to ensure accuracy and clarity. 

4. Post-Market Surveillance and Reporting

Once the product is on the market, you will use the Medical Device Reporting system to report significant problems, evaluate feedback, and keep an eye out for unfavorable events. Software updates that take user input into account guarantee product compliance and consistently enhance patient results. 

Software as a Medical Device vs Traditional Medical Devices

Although SaMD is standalone, its relationship with hardware-based medical devices is closely linked.

1. Complementary Roles

SaMD frequently improves the functionality of physical devices. For example, imaging software SaMD can give enhanced analytics for MRI equipment, allowing for earlier disease identification.

2. Integration with Device Ecosystems

Additional software is needed for many medical devices to configure, calibrate, or visualize data. Trust and usability are increased when your SaMD and hardware components communicate seamlessly.

3. Lifecycle Management Across Platforms

The life cycle expectations for hardware and software differ; whereas software changes happen quickly, equipment can remain in use for years. To provide end-to-end safety, version control, validation, and user training must be synchronized across both domains.

4. Updateability

Unlike physical devices, SaMD may be updated and improved regularly, allowing for rapid feature additions, problem fixes, and adaptation to new medical data.

AI and Machine Learning Software as a Medical Device (AI/ML SaMD)

AI-powered healthcare software is not automatically considered a medical device. The FDA first evaluates what the software is intended to do. 

An AI function may fall under FDA oversight when it performs a medical purpose such as diagnosing a condition, recommending treatment, analyzing patient-specific medical data, or controlling another medical device.

When an AI or machine learning function qualifies as software as a medical device, developers should address:

• Training and test data: Use relevant, representative, and sufficiently diverse data.
• Performance validation: Evaluate accuracy, sensitivity, specificity, failure modes, and performance across the intended population.
• Bias management: Assess whether performance varies across demographic groups, clinical environments, or device configurations.
• Transparency: Explain the software’s intended use, limitations, inputs, outputs, and role in clinical decision-making.
• Model monitoring: Track performance degradation, data drift, cybersecurity risks, and unexpected outcomes after deployment.
• Change control: Assess whether algorithm updates require a new FDA submission or can be managed through an authorized Predetermined Change Control Plan.

FDA’s final PCCP guidance allows manufacturers to describe planned AI modifications, the methods used to develop and validate those changes, and their expected impact within the original marketing submission. An FDA-authorized PCCP may permit specified changes without a separate marketing submission for every covered modification.

FDA also published lifecycle and marketing-submission recommendations for AI-enabled device software functions in January 2025. That document remains draft guidance and should therefore be treated as a nonbinding proposal rather than an implemented final requirement.

Best Practices for FDA-Compliant SaMD Development

To personalize the process, consider your growth journey to be like building a house rather than hurrying to move in. Each phase, foundation, framing, and finishing, marks important quality and regulatory milestones.

Foundation: User Needs and Requirements

Engage clinicians and end users from the beginning. Capture user stories and clinical workflows to guarantee your software solves real-world challenges.

Framing: Design Controls and Risk Management

Convert user needs into design specifications. Create risk mitigation plans in advance and carry out a hazard analysis similar to FMEA.

Finishing: Verification, Validation, and Submission

Each feature is rigorously tested to its standards. Plan and carry out clinical investigations as needed. Create a submission dossier with clear traceability from requirements to test results.

Common FDA SaMD Compliance Challenges and How to Avoid Them

Achieving medical device software compliance requires more than completing documentation before submission. Regulatory requirements should be incorporated into product claims, software development, testing, risk management, cybersecurity, and postmarket processes from the beginning.

1. Incorrect Device Determination or Classification

A company may classify its product based on the technology rather than its intended medical function.

How to avoid it:

• Define the intended use, patient population, and indications for use early.
• Evaluate every software function separately.
• Search FDA classification regulations and product codes.
• Use the Digital Health Policy Navigator.
• Request FDA feedback through the Q-Submission Program when the pathway remains uncertain.

2. Building the Quality System Too Late

Creating quality records after development can produce incomplete design history, weak change control, and missing traceability.

How to avoid it:

• Establish the quality management system before major development begins.
• Connect product requirements, risks, design decisions, testing, and approvals.
• Maintain records as work is performed rather than reconstructing them before submission.
• Align processes with the FDA Quality Management System Regulation.

The QMSR became effective on February 2, 2026, and incorporates ISO 13485:2016 into 21 CFR Part 820, together with additional FDA requirements.

3. Incomplete Software Documentation

Submission delays often occur when requirements, risks, architecture, test results, and software changes cannot be traced to one another.

How to avoid it:

• Maintain a software description and requirements specification.
• Document architecture, interfaces, inputs, outputs, and data flows.
• Link hazards and risk controls to requirements and test evidence.
• Maintain version history and unresolved anomaly records.
• Determine whether Basic or Enhanced Documentation applies.

FDA recommends Enhanced Documentation when a software failure or flaw could create a probable risk of death or serious injury.

4. Insufficient Verification and Validation

Testing only normal workflows may leave clinically significant failure modes undiscovered.

How to avoid it:

• Test normal, boundary, error, misuse, and recovery conditions.
• Validate the software in its actual or appropriately simulated use environment.
• Confirm that the product meets user needs and its intended medical use.
• Include clinical or performance evidence appropriate to the device claim and risk.

FDA expects planning, traceability, risk assessment, design review, change management, and testing evidence to support the conclusion that the software was properly designed, verified, and validated.

5. Uncontrolled AI Model or Software Changes

Updates to algorithms, training data, interfaces, or intended use may affect safety and effectiveness or trigger a new submission.

How to avoid it:

• Establish a formal software change-assessment process.
• Document the reason, scope, risk, testing, and approval for every change.
• Evaluate whether the change significantly affects safety, effectiveness, or intended use.
• Consider a PCCP for predictable AI-enabled modifications.

6. Cybersecurity Added After Development

Security gaps can affect device availability, data integrity, clinical output, and patient safety.

How to avoid it:

• Perform cybersecurity risk assessment during product design.
• Document system architecture, trust boundaries, authentication, encryption, and update mechanisms.
• Establish vulnerability monitoring, coordinated disclosure, patching, and incident-response processes.
• Include applicable cybersecurity evidence in the premarket submission.

FDA’s February 2026 cybersecurity guidance addresses secure device design, labeling, quality-system considerations, and premarket documentation for devices with cybersecurity risk.

FDA-Compliant SaMD Development with CapMinds

Bringing your Software as a Medical Device to life requires more than innovation; it demands regulatory clarity, technical precision, and seamless integration. At CapMinds, we empower health tech visionaries with end-to-end digital health services tailored for FDA-compliant SaMD development.

Our expertise includes:

• FDA Regulatory Support – Pre-submission guidance, 510(k)/De Novo/PMA strategy
• SaMD Development – Clinical functionality, risk-based classification, QMS integration
• Device Integration – Wearables, imaging software, EHRs, and other clinical systems
• Interoperability – HL7, FHIR, and API-based secure data exchange
• Cybersecurity & Compliance – HIPAA safeguards, encrypted communications, secure updates

From concept to post-market success, CapMinds accelerates your SaMD journey, securely and scalably.

Contact CapMinds today to turn your health tech idea into a market-ready, FDA-compliant solution.

Talk to CapMinds’ SaMD experts

Frequently Asked Questions

1. How does the FDA determine whether software qualifies as a medical device?

The FDA evaluates the intended use of each software function. Software may qualify as a device when it is intended to diagnose, treat, cure, mitigate, or prevent a disease, or affect the structure or function of the body. Administrative, general wellness, certain electronic health record, data-transfer, and qualifying clinical decision-support functions may be excluded or subject to enforcement discretion.

2. What is the difference between FDA 510(k), De Novo, and PMA for SaMD?

A 510(k) demonstrates substantial equivalence to a legally marketed predicate. De Novo is generally used for a novel low- or moderate-risk device without an appropriate predicate and creates a new Class I or II classification. PMA is the most stringent pathway and requires valid scientific evidence supporting the safety and effectiveness of a Class III device.

3. Does AI-powered healthcare software require FDA clearance?

Not every AI-powered healthcare product requires FDA clearance. The decision depends on the software’s intended use, functionality, risk classification, and whether an exemption applies. 

An AI function used for patient-specific diagnosis, treatment recommendations, or medical-device control may require 510(k) clearance, De Novo authorization, or PMA approval before marketing.

4. What documentation is required for FDA Software as a Medical Device submissions?

Documentation depends on the device, pathway, and applicable Basic or Enhanced Documentation Level. 

FDA generally recommends a documentation-level rationale, software description, risk management file, software requirements specification, architecture diagrams, development and configuration records, verification and validation results, version history, and unresolved anomaly list. Enhanced submissions may also require detailed software design specifications.

Clinical performance evidence, labeling, human-factors documentation, cybersecurity information, interoperability evidence, and AI change-control information may also be needed depending on the product’s claims and features.

5. What are the most common FDA compliance challenges for medical device software companies?

Common challenges include choosing the wrong regulatory pathway, defining overly broad product claims, establishing the quality system too late, maintaining incomplete traceability, performing insufficient clinical or software validation, overlooking cybersecurity, and failing to assess software or AI model changes. 

Early regulatory planning and lifecycle documentation help reduce submission delays and postmarket compliance risks.